Immunotherapy for extensive stage small cell lung cancer

Jose M. Pacheco

Division of Medical Oncology, Department of Internal Medicine, University of Colorado Cancer Center, Aurora Colorado, USA

Correspondence to: Jose M. Pacheco, MD. Assistant Professor, Thoracic Oncology and Developmental Therapeutics, 1665 Aurora Court, Room 5309, Mail Stop F704, Aurora Colorado 80045, USA. Email: jose.m.pacheco@cuanschutz.edu.

Abstract: Small cell lung cancer (SCLC) is an aggressive malignancy. Until recently the standard of care for newly diagnosed patients with extensive-stage disease was chemotherapy consisting of etoposide plus a platinum (EP). The median overall survival (OS) was only about 10 months with this systemic therapy. Immune checkpoint inhibitors were first evaluated as second or subsequent line treatments in extensive stage disease and later in combination with EP in the first-line setting. Recently two randomized phase III trials have demonstrated statistically improved OS with addition of a programmed death ligand-1 (PD-L1) inhibitor to EP. As a result, the standard of care for newly diagnosed patients with extensive-stage SCLC has changed for the first time in decades. However, many patients do not derive benefit from the addition of a PD-L1 inhibitor to EP. In this review we discuss first-line trials of chemoimmunotherapy in extensive stage SCLC and summarize data on second and subsequent line treatment with immune checkpoint inhibitors in immunotherapy-naïve patients. Additionally, we discuss potential biomarkers that could be utilized to select for which patients derive benefit from addition of a PD-L1 inhibitor to EP and propose ways to improve on first-line chemoimmunotherapy.

Keywords: Small cell lung cancer (SCLC); immunotherapy; atezolizumab; durvalumab; programmed death-1 (PD-1)

Submitted Jan 03, 2020. Accepted for publication Jan 06, 2020.
doi: 10.21037/jtd.2020.01.37
View this article at: http://dx.doi.org/10.21037/jtd.2020.01.37

Introduction

Until recently etoposide plus platinum (EP) was the standard of care for newly diagnosed patients with extensive-stage small-cell lung cancer (ES-SCLC). The median overall survival (OS) with EP was approximately 10 months despite high initial objective response rates (ORRs) of 50–70% (1-4). It was hypothesized that SCLC may preferentially benefit from immunotherapy due to a high tumor mutational burden (TMB) and the presence of autoimmune paraneoplastic syndromes in some patients (5,6). Because of this chemoimmunotherapy was evaluated as first-line therapy for ES-SCLC and recently two regimens have demonstrated superiority over EP (7,8).

This review focuses on immune checkpoint inhibitors with chemotherapy for newly diagnosed patients with ES-SCLC, with particular attention being paid to drugs inhibiting either cytotoxic T-lymphocyte antigen 4 (CTLA-4) or programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1). Additionally, data on second and subsequent line immune checkpoint inhibitors for patients with ES-SCLC will be summarized. New strategies will be proposed to improve on first-line chemoimmunotherapy combinations. While biomarkers will be touched upon, they will be discussed more intensively in other parts of this focused issue.

Methods

Trials were identified by searching PubMed without date limits, abstracts from major medical society meetings since 2015 (American Association for Cancer Research Annual Meeting, American Society of Clinical Oncology Annual Meeting, European Society of Medical Oncology Annual Meeting and International Association for the Study of Lung Cancer World Conference on Lung Cancer), and
clinicaltrials.gov using the keywords: atezolizumab and small cell, durvalumab and small cell, ipilimumab and small cell, nivolumab and small cell, pembrolizumab and small cell, tremelimumab and small cell, Caspian and durvalumab, and IMpower133 and atezolizumab. Trials were excluded if they did not report efficacy data specific to ES-SCLC.

**Chemoimmunotherapy as first-line treatment for ES-SCLC**

**Ipilimumab plus chemotherapy**

**Ipilimumab plus carboplatin plus paclitaxel**

A randomized, double-blind, phase II, placebo-controlled trial evaluated ipilimumab plus carboplatin plus paclitaxel vs. carboplatin plus paclitaxel in ES-SCLC. The three treatment arms included carboplatin plus paclitaxel for up to 6 cycles with ipilimumab added from start of cycle 3, carboplatin plus paclitaxel for up to 6 cycle with ipilimumab added from start of cycle 1 and carboplatin plus paclitaxel plus placebo for up to 6 cycles. There was a non-statistically improved OS with the addition of ipilimumab starting from cycle 3 of induction chemo, median OS was 12.9 months (n=42) vs. 9.9 months (n=45), HR 0.75 (95% CI, 0.46–1.23), P=0.13 (9). This resulted in ipilimumab being evaluated with EP in a subsequent phase III study.

**Ipilimumab plus etoposide plus platinum**

A randomized, phase III, placebo-controlled, double-blind trial evaluated EP with or without ipilimumab in newly diagnosed patients with ES-SCLC. The first 6 cycles of systemic therapy were administered every 21 days. EP was administered for cycles 1 and 2, it was continued in conjunction with ipilimumab or placebo during cycles 3 and 4. Ipilimumab or placebo were administered as monotherapies during cycles 5 and 6. The platinum agent could be cisplatin or carboplatin. Cisplatin was administered at 75 mg/m$^2$ on day 1 and carboplatin was dosed at an area under the concentration time curve (AUC) of 5 on day 1. Etoposide was given at 100 mg/m$^2$ on days 1–3 of each cycle. During cycles 3 through 6, ipilimumab or placebo were administered at 10 mg/kg every 3 weeks on day 1. From cycle 7 onwards ipilimumab or placebo were given at the same dose every 12 weeks. Ipilimumab or placebo were continued for up to 36 months of treatment (10).

The primary endpoint was OS in patients receiving at least one dose of ipilimumab or placebo. Patients with asymptomatic, untreated brain metastases could enroll, but those with a history of autoimmune paraneoplastic syndromes were excluded. Consolidative chest radiotherapy was not permitted in cases where there was measurable intrathoracic disease at start of therapy. However, prior chest radiation as part of chemoradiation for limited stage disease was allowed. Patients with a complete response (CR) or partial response (PR) to the first 6 cycles of therapy could receive optimal prophylactic cranial radiation (PCI). There were 11% of patients who received PCI on the EP plus ipilimumab arm and 14% who received PCI on the EP alone arm (10).

The best ORR by investigator assessment was 62% on each arm and median duration of response (DOR) was similar at 4 vs. 3.5 months with the addition of ipilimumab or placebo respectively (Table 1). Treatment related adverse events (TRAEs) of any type were similar on each arm; however, there was a higher incidence of serious adverse events and immune mediated adverse events in patients receiving ipilimumab (Table 1). Additionally, more patients receiving ipilimumab discontinued therapy due to a TRAE when compared to patients receiving placebo, 18% vs. 2%.

The dose intensity of chemotherapy was not compromised in patients receiving ipilimumab despite the higher rate of discontinuation due to TRAEs (10).

The median progression-free survival (PFS) by investigator assessment was similar on both arms, 4.6 months for EP plus ipilimumab and 4.4 months for EP alone (Table 1). Similarly, the median OS was not improved with the addition of ipilimumab to EP, median 11 months with ipilimumab vs. median 10.9 months with placebo, HR 0.94 (95% CI, 0.81–1.09), P=0.3775 (Table 1). The 1-year OS was 40% on each arm. The lack of demonstrated OS benefit was not the result of cross-over as <1% of patients on each treatment arm received subsequent immunotherapy (10).

Subgroup analysis did not demonstrate evidence for a particular group benefiting from the addition of ipilimumab. There was no OS difference by whether patients received cisplatin or carboplatin. Similarly, there was no OS difference by presence or absence of baseline central nervous system involvement (10).

**IMpower133**

A randomized phase III, double-blind, placebo controlled trial evaluated atezolizumab plus EP vs. EP plus placebo. Carboplatin was the only platinum utilized. Up to 4 cycles of EP were given on each arm. PCI was permitted on either arm, but consolidative thoracic radiotherapy was
Table 1: Published phase III trials of immune checkpoint inhibitors with first-line platinum plus etoposide in ES-SCLC

<table>
<thead>
<tr>
<th>Trial</th>
<th>Regimen(s)</th>
<th>Patient number</th>
<th>ORR</th>
<th>Median PFS</th>
<th>Median OS</th>
<th>TRAEs</th>
<th>Immune mediated AEs</th>
<th>Treatment related SAEs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etoposide plus platinum with or without ipilimumab (10)</td>
<td>Ipilimumab plus etoposide plus platinum</td>
<td>476</td>
<td>62%</td>
<td>4.6 months; HR 0.85, P=0.0161</td>
<td>11.0 months; HR 0.94, P=0.3775</td>
<td>Grade 3–5 48%</td>
<td>Any grade 57%; grade 3–5 20%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Placebo plus etoposide plus platinum</td>
<td>478</td>
<td>62%</td>
<td>4.4 months</td>
<td>10.9 months</td>
<td>Grade 3–5 45%</td>
<td>Any grade 28%; grade 3–5 2%</td>
<td></td>
</tr>
<tr>
<td>IMpower133 (7,11)</td>
<td>Atezolizumab plus etoposide plus platinum</td>
<td>201</td>
<td>60%</td>
<td>5.2 months; HR 0.77, P=0.02</td>
<td>12.3 months; HR 0.76, P=0.0154</td>
<td>Grade 3–5 58.1%</td>
<td>Any grade 39.9%; grade 3–4 10.5%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Placebo plus etoposide plus platinum</td>
<td>202</td>
<td>64%</td>
<td>4.3 months</td>
<td>10.3 months</td>
<td>Grade 3–5 57.8%</td>
<td>Any grade 24.5%; grade 3–4 2.5%</td>
<td></td>
</tr>
<tr>
<td>Caspian (8)</td>
<td>Durvalumab plus etoposide plus platinum</td>
<td>269</td>
<td>68%</td>
<td>5.1 months; HR 0.78, P value not available</td>
<td>13.0 months; HR 0.73, P=0.0047</td>
<td>Grade 3–4 46%</td>
<td>Any grade 20%; grade 3–4 5%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Etoposide plus platinum</td>
<td>269</td>
<td>58%</td>
<td>5.4 months</td>
<td>10.3 months</td>
<td>Grade 3–4 52%</td>
<td>Any grade; 3%; grade 3–4 &lt;1%</td>
<td></td>
</tr>
</tbody>
</table>

ORR, objective response rate; PFS, progression-free survival; OS, overall survival; TRAEs, treatment related adverse events; AEs, adverse events; SAEs, serious adverse events; HR, hazard ratio.

not allowed. Atezolizumab or placebo were administered following completion of EP until either progressive disease or other discontinuation criteria were met. Carboplatin was administered at an AUC of 5 on day 1, etoposide at 100 mg/m² on days 1–3 and atezolizumab at 1200 mg or placebo on day 1. Each cycle was 21 days. The primary endpoint compared investigator assessed PFS and OS between the two treatments. The median follow-up was 13.9 months (7).

Patients had to have brain metastases treated prior to enrollment and these metastases must have been stable off steroids following local therapy. Approximately 9% of patients in each treatment group had baseline brain metastases. Patients with autoimmune paraneoplastic syndromes were excluded. Prior chest radiotherapy was permitted if it was part of definitive chemoradiation and diagnosis of ES-SCLC was >6 months following completion of curative intent therapy for limited stage disease. There were 22 patients on each arm who received PCI. Adverse events of any type were not significantly increased with the addition of atezolizumab to EP; however, there was a higher incidence of immune mediated adverse events in the group that received atezolizumab (Table 1). The confirmed ORR by investigator assessment was similar between arms, 60% with atezolizumab plus EP and 64% with EP (Table 1) (7).

The PFS by investigator assessment was improved with atezolizumab plus EP vs. with EP alone, median 5.2 months vs. 4.3 months, 12 month PFS was 13% vs. 5%, HR 0.77 (95% CI, 0.62–0.96), P=0.02 (Table 1). The median number of atezolizumab doses administered was 7 and the median number of placebo doses administered was 6. The PFS curves were overlapping until about the 50% mark, suggesting that nearly half of patients do not benefit from the addition of atezolizumab to EP. Median DOR was not different between the arms. However, the percentage of responders maintaining response at 12 months was 15% for atezolizumab plus EP vs. only 5% for EP alone (7).

At 2 years of follow-up the OS was improved with atezolizumab added to EP vs. with EP alone, median 12.3 vs. 10.3 months, 12 month OS was 52% vs. 38%, HR 0.76 (95% CI, 0.54–0.91), P=0.0154 (Table 1) (11). The OS curves on both arms were overlapping until about 7 months, after which point the curves began to separate in favor of atezolizumab plus EP. There was not a significant tail on the OS curve for atezolizumab plus EP and the relative magnitude of OS benefit was not as great as observed with some chemoimmunotherapy combinations in non-small cell
lungs (NSCLC) (7,11-14).

**Caspian**

This was a randomized, open label, phase III trial evaluating two chemoimmunotherapy combinations vs. EP. Chemoimmunotherapy consisted of EP plus durvalumab with or without tremelimumab. Cisplatin or carboplatin were permitted. The study was powered to compare OS between EP and each of the chemoimmunotherapy arms. However, it was not powered to compare the two different chemoimmunotherapy arms to each other. At the first interim analysis the durvalumab plus EP arm met the predefined threshold for statistical significance, but the durvalumab plus tremelimumab plus EP arm did not. Thus, the first report only described results for the durvalumab plus EP vs. EP comparison (8).

Durvalumab was dosed at 1,500 mg every 3 weeks during chemotherapy and then at the same dose every 4 weeks following completion of chemotherapy. On the experimental arm durvalumab was continued until either disease progression or other discontinuation criteria were met. Chemotherapy was administered for 4 cycles in the chemoimmunotherapy arm and for up to 6 cycles in the chemotherapy alone arm. On the chemotherapy alone arm 63% of patients completed at least 5 cycles of chemotherapy and 57% completed 6 cycles of chemotherapy. Cisplatin was dosed at 75–80 mg/m² on day 1, carboplatin was dosed at an AUC of 5–6 on day 1 and etoposide was dosed at 80–100 mg/m² on days 1–3. Each cycle of chemotherapy or chemoimmunotherapy was administered every 21 days. PCI was permitted in only the chemotherapy alone arm and 8% of patients on this arm received PCI. Patients having received prior chest radiotherapy were excluded and consolidative chest radiotherapy was not allowed (8).

The confirmed ORR by investigator assessment was improved with durvalumab plus EP vs. EP alone, 68% vs. 58% (Table 1). The median DOR was 5.1 months for both groups; however, the percentage of responders who maintained response at 12 months was greater at 23% for durvalumab plus EP vs. only 6% for EP. Adverse events of any type were not significantly increased with the addition of durvalumab to EP. However, immune mediated adverse events of any grade were higher for patients who received durvalumab plus EP (Table 1). The median follow-up was 14 months for censored patients (8).

The investigator assessed median PFS was 5.1 months with durvalumab plus EP and 5.4 months with EP (Table 1).

The PFS curves did not begin to separate until a little past 6 months. The 12-month PFS was improved with durvalumab plus EP vs. EP, 18% vs. 5%. Overall, there was modest improvement in PFS with the addition of durvalumab to EP, HR 0.78 (95% CI, 0.65–0.94). The PFS curves suggest that well over half of the patients did not have a PFS benefit from the addition of durvalumab to EP (8).

There was improved OS for durvalumab plus EP vs. EP, median OS was 13 vs. 10.3 months, 18 months OS was 34% vs. 25%, HR 0.73 (95% CI, 0.59–0.91), P=0.0047 (Table 1). Similar to the PFS curves, the OS curves did not begin to separate in favor of durvalumab plus EP until a little past 6 months (8). Unlike chemoimmunotherapy in NSCLC, the OS benefit was more modest and there does not yet appear to be a significant tail on the curve that would suggest that the OS benefit of durvalumab plus EP will greatly improve with longer follow-up (8,12–14).

**Subsequent line immune checkpoint inhibition in immunotherapy naïve SCLC**

PD-1 axis inhibition plus EP has become the new standard of care for first-line therapy of ES-SCLC in some parts of the World and will likely become a preferred initial option for newly diagnosed ES-SCLC in other regions. This will render second or subsequent line therapy with PD-1 axis inhibitors and/or CTLA-4 inhibitors as generally ineffective options outside the setting of a clinical trial. Novel combinations utilizing a backbone of PD-1 axis inhibition and/or CTLA-4 inhibition may prove beneficial in the future for patients with progressive disease on first-line chemoimmunotherapy. In this section the data on second or subsequent line therapy with PD-1 axis inhibitors and/or CTLA-4 inhibitors in immunotherapy-naïve patients with ES-SCLC is briefly summarized. Each of the regimens discussed below demonstrated prolonged response durations, highlighting the potential of such therapies for some patients.

On single arm studies the PD-1 inhibitors nivolumab and pembrolizumab have both demonstrated efficacy as second or subsequent line therapy of previously treated ES-SCLC (Table 2) (15–20). Both of these PD-1 inhibitors are approved in some parts of the World as third line agents. Nivolumab plus the CTLA-4 inhibitor ipilimumab has demonstrated efficacy in second or subsequent line therapy as well, with particularly high response rates and prolonged survival benefit seen in immunotherapy naïve patients with high TMB by whole exome sequencing (15,16,18,19) (Table 2). In contrast, PD-L1 staining on tumor cells did
<table>
<thead>
<tr>
<th>Trial</th>
<th>Regimen</th>
<th>PD-L1</th>
<th>TMB &lt;sup&gt;a&lt;/sup&gt;</th>
<th>ORR</th>
<th>Median PFS (months)</th>
<th>Median OS (months)</th>
<th>1-year OS</th>
<th>TRAEs Grade ≥3</th>
</tr>
</thead>
<tbody>
<tr>
<td>KEYNOTE-028 (20)</td>
<td>Pembrolizumab 10 mg/kg every 2 weeks</td>
<td>≥1% CPS&lt;sup&gt;b&lt;/sup&gt; or ≥1% in stroma</td>
<td>Any 24</td>
<td>33%&lt;sup&gt;c&lt;/sup&gt;</td>
<td>1.9 (95% CI, 1.7–5.9)</td>
<td>9.7 (95% CI, 4.1–NR)</td>
<td>37.7%</td>
<td>Grade ≥ 3</td>
</tr>
<tr>
<td>KEYNOTE-158 (17)</td>
<td>Pembrolizumab 200 mg every 3 weeks</td>
<td>Any</td>
<td>Any 107</td>
<td>18.7%&lt;sup&gt;d&lt;/sup&gt;</td>
<td>2.0 (95% CI, 1.9–2.1)</td>
<td>8.7 (95% CI, 5.6–12.0)</td>
<td>40%</td>
<td>Grade 3–4</td>
</tr>
<tr>
<td>CheckMate-032 (15,16,18,19)</td>
<td>Nivolumab 3 mg/kg every 2 weeks</td>
<td>Any</td>
<td>High 47</td>
<td>21.3%&lt;sup&gt;e&lt;/sup&gt;</td>
<td>1.4 (95% CI, 1.3–2.7)</td>
<td>5.4 (95% CI, 2.8–8.0)</td>
<td>35%</td>
<td>Grade 3–4</td>
</tr>
<tr>
<td>IFCT-1603 (22)</td>
<td>Atezolizumab 1200 mg every 3 weeks</td>
<td>Any</td>
<td>Any 49</td>
<td>2.3%&lt;sup&gt;f&lt;/sup&gt;</td>
<td>1.4 (95% CI, 1.2–1.5), HR 2.26, P=0.004</td>
<td>9.5 (95% CI, 3.2–14.4), HR 0.84, P=0.60</td>
<td>42.5%</td>
<td>N/A</td>
</tr>
<tr>
<td>Chemotherapy&lt;sup&gt;h&lt;/sup&gt;</td>
<td>Any</td>
<td>Any 24</td>
<td>10%&lt;sup&gt;e&lt;/sup&gt;</td>
<td>4.3 (95% CI, 1.2–5.9)</td>
<td>8.7 (95% CI, 4.1–12.7)</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Durvalumab in ES-SCLC (24)</td>
<td>Durvalumab 10 mg/kg every 2 weeks</td>
<td>Any</td>
<td>Any 21</td>
<td>9.5%&lt;sup&gt;e&lt;/sup&gt;</td>
<td>1.5 (95% CI, 0.9–1.8)</td>
<td>4.8 (95% CI, 1.3–10.4)</td>
<td>28%</td>
<td>Grade 3–4</td>
</tr>
<tr>
<td>Durvalumab and tremelimumab in ES-SCLC (23)</td>
<td>Durvalumab 20 mg/kg plus tremelimumab 1 mg/kg every 4 weeks × 7 doses, then durvalumab plus tremelimumab every 12 weeks × 2 doses, then durvalumab 10 mg/kg every 2 weeks</td>
<td>Any</td>
<td>Any 30</td>
<td>13.3%&lt;sup&gt;c&lt;/sup&gt;</td>
<td>1.8 (95% CI, 1.0–1.9)</td>
<td>7.9 (95% CI, 3.2–15.8)</td>
<td>41.7%</td>
<td>Grade 3–4</td>
</tr>
<tr>
<td>CheckMate-331 (21)</td>
<td>Nivolumab 240 mg every 2 weeks</td>
<td>Any</td>
<td>Any 284</td>
<td>13.7%&lt;sup&gt;c&lt;/sup&gt;</td>
<td>1.4 (95% CI, 1.4–1.5), HR 1.41, P value N/A</td>
<td>7.5 (95% CI, 6.5–9.2), HR 0.86, P=0.11</td>
<td>37%</td>
<td>Grade 3–4</td>
</tr>
<tr>
<td>Amrubicin or topotecan</td>
<td>Any</td>
<td>Any 285</td>
<td>16.5%&lt;sup&gt;c&lt;/sup&gt;</td>
<td>3.8 (95% CI, 3.0–4.2)</td>
<td>8.4 (95% CI, 7.0–10.0)</td>
<td>34%</td>
<td>Grade 3–4</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> TMB was determined in CheckMate-032 by whole exome sequencing and “high” levels were defined as the upper one-third of those evaluated for TMB; <sup>b</sup> CPS: refers to PD-L1 staining on a combination of tumor cells and tumor infiltrating immune cells; <sup>c</sup> investigator assessment; <sup>d</sup> independent review committee assessment; <sup>e</sup> randomized and non-randomized cohort; <sup>f</sup> investigator assessed for patients on the non-randomized cohort and independent review committee assessed for patients on the randomized cohort; <sup>g</sup> non-randomized cohort; <sup>h</sup> chemotherapy on the IFCT-1603 trial could be either carboplatin plus etoposide for fit patients with relapse free intervals ≥90 days from last first-line therapy or topotecan for all other patients. PD-L1, programmed death ligand-1; TMB, tumor mutational burden; ORR, objective response rate; PFS, progression-free survival; OS, overall survival; TRAEs, treatment related adverse events; CPS, combined positive score; CI, confidence interval; NR, not reached; HR, hazard ratio; N/A, not available; ES-SCLC, extensive stage small-cell lung cancer.
not associate with benefit from nivolumab with or without ipilimumab, but a combined PD-L1 score on tumor cells and immune cells did associate with benefit from pembrolizumab (15-20) (Table 2).

Nivolumab was compared against standard of care chemotherapy (topotecan or amrubicin) as second line treatment in patients with progressive disease during or after EP. Nivolumab had significantly worse PFS than either of these chemotherapies. Additionally, OS was not improved with nivolumab (21) (Table 2).

As second line therapy in a randomized phase II trial atezolizumab did not improve outcomes compared to standard of care chemotherapy (topotecan or retreatment with platinum-based doublet). The ORR with atezolizumab was only 2%. The PFS was worse with atezolizumab than with chemotherapy. Additionally, the OS was not improved with atezolizumab (22) (Table 2).

Durvalumab with or without tremelimumab has been evaluated as second or subsequent line therapy for previously treated ES-SCLC. These immunotherapy regimens were not compared head to head against standard of care chemotherapies. The ORRs observed with these immunotherapy regimens were not high. Additionally, in cross-trial comparisons the PFS is worse than with standard of care chemotherapies and there is not a suggestion of significant improvements in OS (23,24) (Table 2).

### Ongoing trials

There are several trials currently evaluating first-line chemoimmunotherapy regimens in newly diagnosed patients with ES-SCLC (Table 3). The KEYNOTE-604 trial is a randomized double-blind, placebo-controlled trial evaluating the addition of the PD-1 inhibitor pembrolizumab to platinum plus etoposide as first-line treatment in 453 patients with ES-SCLC. There has been a press release of initial trial results, but results have yet to be presented at a meeting or in manuscript format. The addition of pembrolizumab to EP significantly improved PFS, HR 0.75 (95%CI, 0.61–0.91). However, the addition of pembrolizumab to EP failed to meet the prespecified boundary for statistical significance with regards to OS [HR 0.80 (95%CI, 0.64–0.98)], despite the confidence interval not overlapping one (25). Additionally, an ongoing phase II study will help determine whether nivolumab plus EP may have enhanced efficacy compared to EP as first-line therapy for ES-SCLC. Trilaciclib, a cyclin dependent kinase 4/6 inhibitor, is currently being evaluated in combination with atezolizumab plus EP as a first-line therapy (26). These ongoing trials are highlighted in Table 3.

<table>
<thead>
<tr>
<th>Study design</th>
<th>Regimen(s)</th>
<th>Primary outcome(s)</th>
<th>Estimated patient number</th>
<th>Estimated completion date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase III, randomized, double-blind, placebo-controlled (KEYNOTE-604)</td>
<td>(I) Pembrolizumab plus platinum plus etoposide; (II) Placebo plus platinum plus etoposide</td>
<td>PFS and OS</td>
<td>453</td>
<td>October 5th, 2021</td>
</tr>
<tr>
<td>Phase III, randomized, open-label (Caspian)</td>
<td>(I) Durvalumab plus tremelimumab plus platinum plus etoposide; (II) Durvalumab plus platinum plus etoposide; (III) Platinum plus etoposide</td>
<td>PFS and OS</td>
<td>988</td>
<td>Feb 28th, 2020</td>
</tr>
<tr>
<td>Phase II, randomized</td>
<td>(I) Platinum plus etoposide plus nivolumab; (II) Platinum plus etoposide</td>
<td>PFS</td>
<td>150</td>
<td>June 2nd, 2020</td>
</tr>
<tr>
<td>Phase II, randomized, double-blind, placebo-controlled</td>
<td>(I) Carboplatin plus etoposide plus atezolizumab plus trilaciclib; (II) Carboplatin plus etoposide plus atezolizumab plus placebo</td>
<td>Ability to reduce chemotherapy induced myelosuppression</td>
<td>105</td>
<td>May 20th, 2020</td>
</tr>
</tbody>
</table>

PFS, progression-free survival; OS, overall survival.
purposes of this review maintenance trials evaluating switch maintenance with immune checkpoint inhibitors are not discussed as they are not felt most pertinent to the current treatment paradigm where immunotherapy is added to EP from the start of induction treatment.

**Discussion**

Multiple questions have arisen following publication of the IMpower133 and Caspian trials. Evaluating the PFS curves on both studies, there were roughly 50% or more of patients who did not benefit from the addition of a PD-L1 inhibitor to EP. Unfortunately, neither trial suggested a biomarker or specific patient characteristic that could help select for who benefits from the addition of a PD-L1 inhibitor to EP (7,8,11). On IMpower133, the presence or absence of baseline brain metastases, presence or absence of liver metastases and TMB (≥10 mutations per megabase vs. <10 or ≥16 mutations per megabase vs. <16 by a blood based test) did not help select for who benefits from the addition of atezolizumab to EP (7). On Caspian the type of platinum (cisplatin or carboplatin) and presence or absence of baseline brain metastases did not help select for who benefits from the addition of durvalumab to EP. While 39% of patients on Caspian had baseline liver metastases, survival data for patients with and without baseline liver metastases was not presented (8).

Ipilimumab added to EP did not lead to improved survival outcomes compared to EP alone in first-line treatment of ES-SCLC and at the moment there is no role for CTLA-4 inhibition in first-line therapy. The dose of ipilimumab utilized in conjunction with EP may have contributed to the lack of benefit, as nearly 1/5 of patients had to stop ipilimumab due to TRAEs as opposed to development of progressive disease (10). It is possible a lower dose may have been more beneficial by enabling more patients to stay on therapy longer.

Whether CTLA-4 inhibition plus PD-1 axis inhibition will be beneficial when combined with EP in the first-line setting remains to be determined and ongoing trials will help answer this question (Table 3). The presence of AT-rich interactive domain-containing 1A (ARID1A) mutations have been associated with benefit from combined CTLA-4 plus PD-L1 inhibition in NSCLC, but not from PD-L1 inhibition alone (27). ARID1A mutations are present in 2.5–3.5% of cases of SCLC (28). Whether mutations in ARID1A associate with benefit from CTLA-4 inhibition plus PD-1 axis inhibition with or without EP in SCLC remains to be determined. DNA polymerase epsilon (POLE) and DNA polymerase delta-1 (POLD1) mutations have been associated with high TMB in other tumor types (29). Presence of these mutations has been suggested to associate with better outcomes in patients receiving immune checkpoint inhibition (30). POLE mutations are present in 2.5–4.5% of cases of SCLC and POLD1 mutations are present in 1.5–2.5% of cases of SCLC (28). Whether these mutations help predict benefit from immune checkpoint inhibition plus EP in SCLC is unknown. Kelch-like ECH-associated protein 1 (KEAP1) mutations have been associated with lack of significant improvement from addition of PD-1 inhibition to chemotherapy in NSCLC (31). KEAP1 mutations are present in up to 3.5% of cases of SCLC.
SCLC and whether mutations in KEAP1 may predict lack of benefit from addition of immune checkpoint inhibition to EP in SCLC remains to be determined (28). Further investigation will help determine whether these or other biomarkers may help predict benefit from CTLA-4 inhibition and/or PD-1 axis inhibition in first-line treatment of ES-SCLC (Figure 1).

It is unlikely that CTLA-4 inhibition plus PD-1 axis inhibition will be beneficial for most patients after progression on EP plus a PD-1 axis inhibitor. In melanoma, a disease much more responsive to CTLA-4 inhibition, response rates were only about 15% to ipilimumab following progression on a PD-1 inhibitor (32). Additionally, on CheckMate-032, there were 9 patients who crossed over to nivolumab plus ipilimumab after progression on nivolumab monotherapy and none of these 9 patients had an objective response (16).

Ipilimumab preferentially activates peripheral T-cells, as opposed to intratumoral T-cells. PD-1 axis inhibitors preferentially activate intratumoral T-cells as opposed to peripheral T-cells (33). Ipilimumab did not improve outcomes when added to EP; however, the addition of a PD-L1 inhibitor to EP did improve efficacy (7,8,10,11). Thus, one can hypothesize that activation of intratumoral T-cells may have greater importance than activation of peripheral T-cells for mounting an effective anti-tumor immune response in SCLC and/or that ipilimumab may be more effective if paired with an agent that aids immune cell delivery from the vasculature into the tumor microenvironment (e.g., a vascular endothelial growth factor pathway inhibitor). Whether baseline levels of intratumoral CD4+ and/or CD8+ T-cells could serve as predictors of benefit for addition of PD-1 axis inhibition to EP in ES-SCLC is unknown.

Some patients with SCLC may have autoimmune paraneoplastic syndromes (6). However, due to safety concerns the phase III trials discussed above did not allow patients with a history of autoimmune paraneoplastic syndromes to enroll (7,8,10,11). Additionally, IMpower133 did not permit patients with asymptomatic untreated brain metastases to enroll; however, the Caspian study did (7,8,11). Unfortunately, the Caspian trial did not present data specific to patients with asymptomatic, untreated brain metastases (8). Also, patients with eastern cooperative oncology group performance status ≥2 were not enrolled on either IMpower133 or Caspian (7,8,11). Whether PD-1 axis inhibition added to EP would be safe and/or effective in the patient populations mentioned above is unknown (Figure 1).

Patients on IMpower133 received up to 4 cycles of EP on the chemotherapy alone arm; however, on Caspian patients received up to 6 cycles of EP on the chemotherapy arm (7,8,11). Whether there is an optimal number of EP cycles to administer in conjunction with PD-1 axis inhibition is unclear. It does appear that 4 cycles could be just as beneficial as 6 cycles, as the median OS was 10.3 months on the control arm of both IMpower133 and Caspian (7,8,11). Whether fewer than 4 cycles of EP can be administered in conjunction with immune checkpoint inhibition without a decrease in efficacy of chemoimmunotherapy is unknown.

On both the IMpower133 and Caspian trials the PFS curves and OS curves did not separate until after 6 months in favor of the chemoimmunotherapy arms (7,8,11). This brings up the possibility that maintenance therapy may be driving some of this benefit. Prior switch maintenance studies involving sequential pembrolizumab or sequential nivolumab plus/minus ipilimumab did not suggest survival improvement following EP for patients with stable disease (SD), PR or CR to induction chemotherapy (34,35). However, both atezolizumab and durvalumab were given as continuation maintenance following induction PD-L1 inhibition plus EP, as opposed to being administered as sequential switch maintenance following EP alone (7,8,11). It is very possible that responses may be longer lasting with immune checkpoint inhibition added from the start of induction chemoimmunotherapy and that continuation maintenance with an immune checkpoint inhibitor may be helping increase the durability of these responses. The only way to definitively determine whether this was true would be a trial where patients were randomized to continuation PD-1 axis inhibition vs. observation following completion of induction chemoimmunotherapy. However, such a trial is unlikely to occur because of ethical issues as well as patients not wanting to risk forgoing a generally well tolerated monotherapy treatment.

In both IMpower133 and Caspian the administration of continuation maintenance with PD-L1 inhibition occurred until development of progressive disease or other discontinuation criteria were met (7,8,11). However, it is unclear what is the optimal duration of continuation maintenance with atezolizumab or durvalumab for patients with ES-SCLC following induction chemoimmunotherapy (Figure 1). Whether normalization of circulating tumor DNA (ctDNA) by a highly sensitive assay in patients with previously detectable ctDNA levels could help guide who may safely stop PD-L1 inhibition during the maintenance phase is unknown.
Both the IMpower133 and Caspian trials demonstrated similarly improved OS survival with the addition of PD-L1 inhibition to EP. However, the median OS benefit was less than 3 months on both trials and there does not yet appear to be a significant tail on the curves as we have seen with first-line immunotherapy in NSCLC. This suggests that perhaps there may be more and/or different immunotherapy resistance mechanisms in SCLC. It is unlikely cross-over masked the OS benefit in either of these trials, as the cross-over to immunotherapy was only 7% on IMpower133 for the EP alone group and on the Caspian trial it was only 5% for the EP alone group.

Additionally, PD-1 axis and/or CTLA-4 inhibition have limited survival benefit when administered as second or subsequent line therapy following progression on EP. Both IMpower133 and Caspian have led to a new standard of care in first-line ES-SCLC; however, there is still a lot of room for improvement.

Recently it has been proposed that SCLC may be divided into four molecular subtypes with distinct gene expression profiles: SCLC-A (high achaete-scute homologue 1), SCLC-N (high neurogenic differentiation factor 1), SCLC-P (high POU class 2 homeobox 3) and SCLC-Y (high yes-associated protein 1). The different immune cell infiltrates and immune response gene signatures in these subtypes has not been reported. It could be beneficial to look for associations between these molecular subtypes and efficacy outcomes to chemoimmunotherapy regimens in SCLC.

Oncolytic viruses have been suggested in melanoma to enhance efficacy of immune checkpoint inhibitors. The Seneca Valley Virus (SVV) is an oncolytic virus that was evaluated as a switch maintenance therapy in ES-SCLC patients with at least CR, PR or SD to first-line EP. There was no benefit for SVV as a switch maintenance strategy; however, there was no biomarker selection.

SLFN-11, schlafen family member 11; IHC, immunohistochemistry; PARP, poly ADP ribose polymerase; VEGF, vascular endothelial growth factor.

Figure 2 Potential ways to improve first-line chemoimmunotherapy in ES-SCLC. ES-SCLC, extensive-stage small-cell lung cancer; SLFN-11, schlafen family member 11; IHC, immunohistochemistry; PARP, poly ADP ribose polymerase; VEGF, vascular endothelial growth factor.

 POTENTIAL WAYS TO IMPROVE FIRST LINE CHEMIOIMMUNOTHERAPY IN ES-SCLC

Biomarker selection | Induction chemoimmunotherapy | Continuation maintenance immunotherapy
---|---|---
SLFN-11 overexpression by IHC | Add a PARP inhibitor here | Add/continue a PARP inhibitor here if clinical benefit to induction
C-MYC overexpression by IHC | Add an Aurora Kinase inhibitor here | Add/continue an Aurora Kinase inhibitor here if clinical benefit to induction
Patients double negative for markers above | Add Anlotinib or a VEGF pathway inhibitor | Add/continue anlotinib or a VEGF pathway inhibitor here if clinical benefit to induction

Combinations investigating deviations of the above and other biomarker directed strategies will be important.

In a subsequent line therapy trial for patients...
with ES-SCLC the overexpression of c-MYC by immunohistochemistry was associated with significantly better PFS from the aurora kinase A inhibitor alisertib added to paclitaxel (44). Mouse models of breast cancer have suggested that inhibition of aurora kinase A with alisertib may synergize with PD-L1 inhibition through depletion of myeloid derived suppressor cells, depletion of tumor promoting macrophages and an increase in anti-tumor T lymphocytes within the tumor microenvironment (45). Whether aurora kinase B inhibition would similarly promote anti-tumor immunity is unknown. It is possible that patients with c-MYC overexpression by immunohistochemistry may benefit from the addition of an aurora kinase inhibitor to chemoimmunotherapy either upon starting induction or from the beginning of continuation maintenance (Figure 2).

Vascular endothelial growth factor (VEGF) pathway inhibition has been demonstrated in preclinical and clinical studies to enhance anti-tumor immunity (46-49). Anlotinib is a multi-kinase inhibitor that also inhibits VEGF signaling. Anlotinib has demonstrated efficacy in patients with previously treated ES-SCLC (50). Patients without overexpression of SLFN11 or c-MYC by immunohistochemistry may benefit from the addition of a VEGF pathway inhibitor or anlotinib to chemoimmunotherapy at either the beginning of induction or from the beginning of continuation maintenance (Figure 2).

Adding a fourth agent into the induction phase with chemoimmunotherapy or a second agent to PD-1 axis inhibition at the start of continuation maintenance may be one avenue to improve on first-line chemoimmunotherapy in ES-SCLC. The markers detailed above may help guide the selection of the appropriate agent in a theoretical biomarker selection trial (Figure 2). Such a trial would be one of the initial biomarker investigative strategies in the first-line setting for ES-SCLC. However, there could be challenges enrolling onto such a trial due to small diagnostic tissue specimens and whether such regimens would be safe/acceptable to be determined.

Recent trials combining PD-L1 inhibitors with EP for newly diagnosed patients with ES-SCLC have changed the standard of care first-line therapy for this disease. However, the improvements seen are marginal and far from sufficient. Construction of patient derived xenografts from circulating tumor cells obtained prior to administration of chemoimmunotherapy, during treatment in patients with clinical benefit and at time of development of progressive disease could prove useful in learning about chemoimmunotherapy biomarkers and resistance mechanisms. Further research into biomarkers for SCLC will be essential to advance the field, as will clinical trials investigating novel combinations.

Acknowledgments

None.

Footnote

Conflicts of Interest: Advisory board/consulting role for AstraZeneca, Gerson Lehrman Group, Hengrui Pharmaceuticals, Novartis and Pfizer. Honorarium from Genentech and Takeda. Research funding from Pfizer to institution.

Ethical Statement: The author is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References

Outcomes Across Multiple Cancer Types, JAMA Oncol 2019. [Epub ahead of print].


46. Cheng AL, Qin S, Ikeda M, et al. IMbrave150: Efficacy and Safety Results From a Ph 3 Study Evaluating Atezolizumab (atezo) + Bevacizumab (bev) vs Sorafenib (Sor) as First Treatment (tx) for Patients (pts) With Unresectable Hepatocellular Carcinoma (HCC). Signapore: European Society of Medical Oncology Asia Congress, 2019.


